KR20240154641A - Her-3, 및 her-2 또는 egfr에 결합하는 이중특이적 항체 - Google Patents

Her-3, 및 her-2 또는 egfr에 결합하는 이중특이적 항체 Download PDF

Info

Publication number
KR20240154641A
KR20240154641A KR1020247032358A KR20247032358A KR20240154641A KR 20240154641 A KR20240154641 A KR 20240154641A KR 1020247032358 A KR1020247032358 A KR 1020247032358A KR 20247032358 A KR20247032358 A KR 20247032358A KR 20240154641 A KR20240154641 A KR 20240154641A
Authority
KR
South Korea
Prior art keywords
domain
seq
fab
antibody
bispecific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247032358A
Other languages
English (en)
Korean (ko)
Inventor
유진 주코브스키
피에르-엠마뉘엘 제라르
크리스뗄 라르부르
라비아 에밀리아
티에리 샤르데
앙드레 펠레그랭
Original Assignee
바이오뮤넥스 파마슈티컬스
유니베르시테 드 몽펠리에
앵스띠뛰 레지오날 뒤 깡세르 드 몽뻴리에 (아이씨엠)
앵스띠뛰 레지오날 뒤 깡세르 드 몽–y리에 (아이씨엠)
인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인쎄름)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오뮤넥스 파마슈티컬스, 유니베르시테 드 몽펠리에, 앵스띠뛰 레지오날 뒤 깡세르 드 몽뻴리에 (아이씨엠), 앵스띠뛰 레지오날 뒤 깡세르 드 몽–y리에 (아이씨엠), 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인쎄름) filed Critical 바이오뮤넥스 파마슈티컬스
Publication of KR20240154641A publication Critical patent/KR20240154641A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020247032358A 2022-03-02 2023-03-01 Her-3, 및 her-2 또는 egfr에 결합하는 이중특이적 항체 Pending KR20240154641A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22305242 2022-03-02
EP22305242.4 2022-03-02
PCT/EP2023/055243 WO2023166098A1 (en) 2022-03-02 2023-03-01 Bispecific antibodies binding to her-3 and to either her-2 or egfr

Publications (1)

Publication Number Publication Date
KR20240154641A true KR20240154641A (ko) 2024-10-25

Family

ID=80930221

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247032358A Pending KR20240154641A (ko) 2022-03-02 2023-03-01 Her-3, 및 her-2 또는 egfr에 결합하는 이중특이적 항체

Country Status (9)

Country Link
US (1) US20250282892A1 (https=)
EP (1) EP4486774A1 (https=)
JP (1) JP2025510539A (https=)
KR (1) KR20240154641A (https=)
CN (1) CN119451982A (https=)
AU (1) AU2023228330A1 (https=)
CA (1) CA3244947A1 (https=)
TW (1) TW202342538A (https=)
WO (1) WO2023166098A1 (https=)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
SG190572A1 (en) * 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2603527A1 (en) 2010-08-10 2013-06-19 Glycotope GmbH Humanized egfr antibodies
EP2543680A1 (en) 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
JP5786839B2 (ja) 2012-12-05 2015-09-30 株式会社デンソー エポキシ樹脂組成物および接着構造体の製造方法
US11421028B2 (en) * 2016-02-06 2022-08-23 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
AU2019412561A1 (en) 2018-12-24 2021-08-12 Sanofi Multispecific binding proteins with mutant Fab domains

Also Published As

Publication number Publication date
JP2025510539A (ja) 2025-04-15
CN119451982A (zh) 2025-02-14
AU2023228330A1 (en) 2024-09-19
CA3244947A1 (en) 2023-09-07
EP4486774A1 (en) 2025-01-08
TW202342538A (zh) 2023-11-01
WO2023166098A1 (en) 2023-09-07
US20250282892A1 (en) 2025-09-11

Similar Documents

Publication Publication Date Title
JP7589314B2 (ja) 抗ｐｄ－１／抗ｖｅｇｆａ二官能性抗体、その医薬組成物およびその使用
KR102360742B1 (ko) Egfr 및 her2 를 표적하는 이특이적 항체
JP7736772B2 (ja) ＥＧＦＲ及びｃＭＥＴに結合する抗体
KR102469286B1 (ko) 항-pd1 단일클론 항체, 이의 약제학적 조성물 및 이의 용도
KR102361412B1 (ko) Cd38 및 pd-l1에 대한 결합 분자
US20250236682A1 (en) Antigen-binding protein comprising two fc domains and use thereof
US20250382386A1 (en) Anti-alk-1 antibody and use thereof
US20180017572A1 (en) Assay and method for determining cdc eliciting antibodies
US20250282892A1 (en) Bispecific antibodies binding to her-3 and to either her-2 or egfr
HK40073118A (en) Binding molecules to cd38 and pd-l1
HK40073118B (en) Binding molecules to cd38 and pd-l1
HK40002344B (en) Binding molecules to cd38 and pd-l1

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000